Breakthrough cancer pain (BTcP): A synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy

Furio Zucco, Cesare Bonezzi, Diego Fornasari

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Pain presents in 80% of patients with advanced cancer, and 30% have periods of increased pain due to fluctuating intensity, known as breakthrough cancer pain (BTcP). BTcP is high-intensity, short-duration pain occurring in several episodes per day and is non-responsive to treatment. The clinical approach to BTcP is variable. A review of the literature was performed to provide clinicians and practitioners with a rational synthesis of the ongoing scientific debate on BTcP and to provide a basis for optimal clinical approach to BTcP in adult Italian patients. Data show that circadian exacerbations of pain should be carefully monitored, differentiating, if possible, between fluctuations of background pain (BP), end-of-dose effect, and BTcP. BTcP should be monitored in all care contexts in clinical practice and each care facility must have all the medications and products approved for use in BTcP at their disposal. Data show that knowledge about medications for BTcP is lacking: medications for BTcP treatment are not interchangeable, although containing the same active substance; each physician must know the specific characteristics of each medication, its pharmacological properties, limitations in clinical practice, specifics relating to titration and repeatability of administration, and technical specifics relating to the accessibility and delivery. Importantly, before choosing a rapid-onset opioid (ROO), it is essential to deeply understand the status of patient and the characteristics of their family unit/caregivers, taking into account the patient's progressive loss of autonomy and/or cognitive-relational functionality. When BTcP therapy is initiated or changed, special attention must be paid to training the patient and family members/caregivers, providing clear instructions regarding the timing of drug administration. The patient must already be treated effectively with opioids before introducing ROOs for control of BTcP.

Original languageEnglish
Pages (from-to)657-682
Number of pages26
JournalAdvances in Therapy
Volume31
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

Breakthrough Pain
Italy
Pain
Therapeutics
Opioid Analgesics
Caregivers
Cancer Pain

Keywords

  • Breakthrough cancer pain (BTcP)
  • Cancer
  • Fentanyl
  • Pain
  • Pain exacerbation
  • Palliative care

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Breakthrough cancer pain (BTcP) : A synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy. / Zucco, Furio; Bonezzi, Cesare; Fornasari, Diego.

In: Advances in Therapy, Vol. 31, No. 7, 2014, p. 657-682.

Research output: Contribution to journalArticle

@article{42093176ffa44939aa7e06c475e9525d,
title = "Breakthrough cancer pain (BTcP): A synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy",
abstract = "Pain presents in 80{\%} of patients with advanced cancer, and 30{\%} have periods of increased pain due to fluctuating intensity, known as breakthrough cancer pain (BTcP). BTcP is high-intensity, short-duration pain occurring in several episodes per day and is non-responsive to treatment. The clinical approach to BTcP is variable. A review of the literature was performed to provide clinicians and practitioners with a rational synthesis of the ongoing scientific debate on BTcP and to provide a basis for optimal clinical approach to BTcP in adult Italian patients. Data show that circadian exacerbations of pain should be carefully monitored, differentiating, if possible, between fluctuations of background pain (BP), end-of-dose effect, and BTcP. BTcP should be monitored in all care contexts in clinical practice and each care facility must have all the medications and products approved for use in BTcP at their disposal. Data show that knowledge about medications for BTcP is lacking: medications for BTcP treatment are not interchangeable, although containing the same active substance; each physician must know the specific characteristics of each medication, its pharmacological properties, limitations in clinical practice, specifics relating to titration and repeatability of administration, and technical specifics relating to the accessibility and delivery. Importantly, before choosing a rapid-onset opioid (ROO), it is essential to deeply understand the status of patient and the characteristics of their family unit/caregivers, taking into account the patient's progressive loss of autonomy and/or cognitive-relational functionality. When BTcP therapy is initiated or changed, special attention must be paid to training the patient and family members/caregivers, providing clear instructions regarding the timing of drug administration. The patient must already be treated effectively with opioids before introducing ROOs for control of BTcP.",
keywords = "Breakthrough cancer pain (BTcP), Cancer, Fentanyl, Pain, Pain exacerbation, Palliative care",
author = "Furio Zucco and Cesare Bonezzi and Diego Fornasari",
year = "2014",
doi = "10.1007/s12325-014-0130-z",
language = "English",
volume = "31",
pages = "657--682",
journal = "Advances in Therapy",
issn = "0741-238X",
publisher = "Springer Healthcare",
number = "7",

}

TY - JOUR

T1 - Breakthrough cancer pain (BTcP)

T2 - A synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy

AU - Zucco, Furio

AU - Bonezzi, Cesare

AU - Fornasari, Diego

PY - 2014

Y1 - 2014

N2 - Pain presents in 80% of patients with advanced cancer, and 30% have periods of increased pain due to fluctuating intensity, known as breakthrough cancer pain (BTcP). BTcP is high-intensity, short-duration pain occurring in several episodes per day and is non-responsive to treatment. The clinical approach to BTcP is variable. A review of the literature was performed to provide clinicians and practitioners with a rational synthesis of the ongoing scientific debate on BTcP and to provide a basis for optimal clinical approach to BTcP in adult Italian patients. Data show that circadian exacerbations of pain should be carefully monitored, differentiating, if possible, between fluctuations of background pain (BP), end-of-dose effect, and BTcP. BTcP should be monitored in all care contexts in clinical practice and each care facility must have all the medications and products approved for use in BTcP at their disposal. Data show that knowledge about medications for BTcP is lacking: medications for BTcP treatment are not interchangeable, although containing the same active substance; each physician must know the specific characteristics of each medication, its pharmacological properties, limitations in clinical practice, specifics relating to titration and repeatability of administration, and technical specifics relating to the accessibility and delivery. Importantly, before choosing a rapid-onset opioid (ROO), it is essential to deeply understand the status of patient and the characteristics of their family unit/caregivers, taking into account the patient's progressive loss of autonomy and/or cognitive-relational functionality. When BTcP therapy is initiated or changed, special attention must be paid to training the patient and family members/caregivers, providing clear instructions regarding the timing of drug administration. The patient must already be treated effectively with opioids before introducing ROOs for control of BTcP.

AB - Pain presents in 80% of patients with advanced cancer, and 30% have periods of increased pain due to fluctuating intensity, known as breakthrough cancer pain (BTcP). BTcP is high-intensity, short-duration pain occurring in several episodes per day and is non-responsive to treatment. The clinical approach to BTcP is variable. A review of the literature was performed to provide clinicians and practitioners with a rational synthesis of the ongoing scientific debate on BTcP and to provide a basis for optimal clinical approach to BTcP in adult Italian patients. Data show that circadian exacerbations of pain should be carefully monitored, differentiating, if possible, between fluctuations of background pain (BP), end-of-dose effect, and BTcP. BTcP should be monitored in all care contexts in clinical practice and each care facility must have all the medications and products approved for use in BTcP at their disposal. Data show that knowledge about medications for BTcP is lacking: medications for BTcP treatment are not interchangeable, although containing the same active substance; each physician must know the specific characteristics of each medication, its pharmacological properties, limitations in clinical practice, specifics relating to titration and repeatability of administration, and technical specifics relating to the accessibility and delivery. Importantly, before choosing a rapid-onset opioid (ROO), it is essential to deeply understand the status of patient and the characteristics of their family unit/caregivers, taking into account the patient's progressive loss of autonomy and/or cognitive-relational functionality. When BTcP therapy is initiated or changed, special attention must be paid to training the patient and family members/caregivers, providing clear instructions regarding the timing of drug administration. The patient must already be treated effectively with opioids before introducing ROOs for control of BTcP.

KW - Breakthrough cancer pain (BTcP)

KW - Cancer

KW - Fentanyl

KW - Pain

KW - Pain exacerbation

KW - Palliative care

UR - http://www.scopus.com/inward/record.url?scp=84905909175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905909175&partnerID=8YFLogxK

U2 - 10.1007/s12325-014-0130-z

DO - 10.1007/s12325-014-0130-z

M3 - Article

C2 - 25005168

AN - SCOPUS:84905909175

VL - 31

SP - 657

EP - 682

JO - Advances in Therapy

JF - Advances in Therapy

SN - 0741-238X

IS - 7

ER -